Enhancer Remodeling-Driven Mevalonate Pathway Confers Resistance to KRAS Inhibitor in Colorectal Cancer
The study aims to investigate acquired resistance to KRAS-G12C inhibitor sotorasib in SW837 colorectal cancer cells. WES data of parental and resistant cells will be used to identify genetic alterations associated with resistance, complementing our epigenetic findings that enhancer remodeling and mevalonate pathway activation drive resistance via KRAS membrane trafficking. This work has implications for overcoming resistance in KRAS-mutant cancers.